Payment overview · 2025
General Payments
$398.21
20 reported records · 10 companies
Healthcare provider profile · identity verified
Christopher O Harper, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WARRIOR, AL · NPI 1770575854
Verified facts
What the public records show
CMS Open Payments records show Christopher O Harper, MD received $398.21 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.34 | 32.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.57 | 15.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.04 | 11.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.58 | 8.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.46 | 6.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.94 | 6.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.04 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.29 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.51 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.44 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.21 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.11 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.11 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.57 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.46 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.46 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 187 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
187 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 588 | 180 |
| Gabapentin | Gabapentin | 543 | 157 |
| Tramadol Hcl | Tramadol Hcl | 466 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 325 | 110 |
| Losartan Potassium | Losartan Potassium | 297 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 66 |
| Metformin Hcl | Metformin Hcl | 271 | 91 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 257 | 34 |
| Lisinopril | Lisinopril | 256 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 79 |
| Furosemide | Furosemide | 235 | 85 |
| Montelukast Sodium | Montelukast Sodium | 221 | 74 |
| Omeprazole | Omeprazole | 221 | 67 |
| Clonazepam | Clonazepam | 194 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 67 |
| Jardiance | Empagliflozin | 187 | 43 |
| Carvedilol | Carvedilol | 182 | 56 |
| Eliquis | Apixaban | 181 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 167 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 165 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 80 |
| Glipizide | Glipizide | 162 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 51 |
| Trazodone Hcl | Trazodone Hcl | 155 | 52 |
| Irbesartan | Irbesartan | 151 | 54 |
| Prednisone | Prednisone | 147 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 41 |
| Famotidine | Famotidine | 118 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 23 |
| Sertraline Hcl | Sertraline Hcl | 113 | 42 |
| Buspirone Hcl | Buspirone Hcl | 112 | 33 |
| Meloxicam | Meloxicam | 111 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 40 |
| Potassium Chloride | Potassium Chloride | 110 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 31 |
| Nystatin | Nystatin | 97 | 31 |
| Aripiprazole | Aripiprazole | 96 | 23 |
| Valsartan | Valsartan | 93 | 29 |
| Metformin Hcl Er | Metformin Hcl | 92 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 87 | 30 |
| Spironolactone | Spironolactone | 87 | 28 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Allopurinol | Allopurinol | 80 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 27 |
| Alprazolam | Alprazolam | 79 | 12 |
| Memantine Hcl | Memantine Hcl | 73 | 16 |
| Lorazepam | Lorazepam | 71 | 12 |
| Promethazine Hcl | Promethazine Hcl | 70 | 18 |
| Atenolol | Atenolol | 66 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 65 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 12 |
| Topiramate | Topiramate | 63 | 28 |
| Xarelto | Rivaroxaban | 63 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | suppressed |
| Methocarbamol | Methocarbamol | 57 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 41 |
| Warfarin Sodium | Warfarin Sodium | 53 | 12 |
| Mirtazapine | Mirtazapine | 52 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 16 |
| Simvastatin | Simvastatin | 49 | 16 |
| Fenofibrate | Fenofibrate | 47 | 11 |
| Nitroglycerin | Nitroglycerin | 47 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 35 |
| Clonidine Hcl | Clonidine Hcl | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 30 |
| Fluconazole | Fluconazole | 45 | 20 |
| Repatha Sureclick | Evolocumab | 45 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | 33 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 44 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 33 |
| Methotrexate | Methotrexate Sodium | 38 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | 12 |
| Amoxicillin | Amoxicillin | 37 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Ozempic | Semaglutide | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 18 |
| Finasteride | Finasteride | 36 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 16 |
| Ketoconazole | Ketoconazole | 33 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 20 |
| Estradiol | Estradiol | 27 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 14 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | 11 |
| Klor-Con M10 | Potassium Chloride | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Epinephrine | Epinephrine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 11 |
| Tresiba | Insulin Degludec | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Ramipril | Ramipril | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Tri-Legest Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.21 · 20 records | Novo Nordisk Inc | Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error